Cargando…

The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)

Sialorrhoea is a frequent symptom of neurological diseases (e.g. Parkinson’s disease, motor neuron disease, cerebral palsy, and stroke) and is defined as excessive saliva accumulation leading to unintentional loss of saliva from the mouth. Sialorrhoea increases the overall burden on the patient and...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgante, Francesca, Bavikatte, Ganesh, Anwar, Fahim, Mohamed, Biju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883364/
https://www.ncbi.nlm.nih.gov/pubmed/31819763
http://dx.doi.org/10.1177/1756286419888601
_version_ 1783474366592319488
author Morgante, Francesca
Bavikatte, Ganesh
Anwar, Fahim
Mohamed, Biju
author_facet Morgante, Francesca
Bavikatte, Ganesh
Anwar, Fahim
Mohamed, Biju
author_sort Morgante, Francesca
collection PubMed
description Sialorrhoea is a frequent symptom of neurological diseases (e.g. Parkinson’s disease, motor neuron disease, cerebral palsy, and stroke) and is defined as excessive saliva accumulation leading to unintentional loss of saliva from the mouth. Sialorrhoea increases the overall burden on the patient and their caregivers, the impact of which can be both physical and psychosocial. Treatments for sialorrhoea range from lifestyle and behavioural guidance, to medications, surgery or radiation. Nonpharmacological interventions include advice on posture, swallowing control, cough management, dietary changes, eating and drinking techniques, and behavioural modification; however, these conservative measures may be ineffective for people with progressive neurological conditions. The pharmacological treatment of sialorrhoea is challenging because medications licensed for this purpose are limited, but treatments can include anticholinergic drugs and botulinum toxins. Surgical treatment of sialorrhoea is typically reserved as a last resort for patients. IncobotulinumtoxinA (Xeomin®) is the first botulinum toxin type A to receive US and UK marketing authorization for the symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults. In this review, we discuss and compare the frequency and method of administration, location of treatment delivery, approximate annual costs and main side effects of botulinum toxin and different anticholinergic drugs. Management of patients with chronic neurological conditions requires input from multiple specialist teams and thus a multidisciplinary team (MDT) approach is considered fundamental to ensure that care is consistent and tailored to patients’ needs. To ensure that adult patients with neurological conditions receive the best care and sialorrhoea is well managed, we suggest a potential clinical care pathway for sialorrhoea with a MDT approach, which healthcare professionals could aspire to.
format Online
Article
Text
id pubmed-6883364
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-68833642019-12-09 The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®) Morgante, Francesca Bavikatte, Ganesh Anwar, Fahim Mohamed, Biju Ther Adv Neurol Disord Supplement Sialorrhoea is a frequent symptom of neurological diseases (e.g. Parkinson’s disease, motor neuron disease, cerebral palsy, and stroke) and is defined as excessive saliva accumulation leading to unintentional loss of saliva from the mouth. Sialorrhoea increases the overall burden on the patient and their caregivers, the impact of which can be both physical and psychosocial. Treatments for sialorrhoea range from lifestyle and behavioural guidance, to medications, surgery or radiation. Nonpharmacological interventions include advice on posture, swallowing control, cough management, dietary changes, eating and drinking techniques, and behavioural modification; however, these conservative measures may be ineffective for people with progressive neurological conditions. The pharmacological treatment of sialorrhoea is challenging because medications licensed for this purpose are limited, but treatments can include anticholinergic drugs and botulinum toxins. Surgical treatment of sialorrhoea is typically reserved as a last resort for patients. IncobotulinumtoxinA (Xeomin®) is the first botulinum toxin type A to receive US and UK marketing authorization for the symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults. In this review, we discuss and compare the frequency and method of administration, location of treatment delivery, approximate annual costs and main side effects of botulinum toxin and different anticholinergic drugs. Management of patients with chronic neurological conditions requires input from multiple specialist teams and thus a multidisciplinary team (MDT) approach is considered fundamental to ensure that care is consistent and tailored to patients’ needs. To ensure that adult patients with neurological conditions receive the best care and sialorrhoea is well managed, we suggest a potential clinical care pathway for sialorrhoea with a MDT approach, which healthcare professionals could aspire to. SAGE Publications 2019-11-28 /pmc/articles/PMC6883364/ /pubmed/31819763 http://dx.doi.org/10.1177/1756286419888601 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Supplement
Morgante, Francesca
Bavikatte, Ganesh
Anwar, Fahim
Mohamed, Biju
The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
title The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
title_full The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
title_fullStr The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
title_full_unstemmed The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
title_short The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
title_sort burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxina (xeomin®)
topic Supplement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883364/
https://www.ncbi.nlm.nih.gov/pubmed/31819763
http://dx.doi.org/10.1177/1756286419888601
work_keys_str_mv AT morgantefrancesca theburdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin
AT bavikatteganesh theburdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin
AT anwarfahim theburdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin
AT mohamedbiju theburdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin
AT morgantefrancesca burdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin
AT bavikatteganesh burdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin
AT anwarfahim burdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin
AT mohamedbiju burdenofsialorrhoeainchronicneurologicalconditionscurrenttreatmentoptionsandtheroleofincobotulinumtoxinaxeomin